Xbrane Biopharma: Clarified timeline BsUFA expected by Q3 2026 - Redeye

Xbrane today provided an update on the expected timeline for the resubmission of the BLA for its ranibizumab biosimilar, indicating a planned March resubmission. This would imply an expected BsUFA date in September, representing slightly shorter lead time than we had previously anticipated.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139823/xbrane-biopharma-clarified-timeline-bsufa-expected-by-q3-2026?utm_source=finwire&utm_medium=RSS